Accendra Health Forecasts Potential 30% Decline in 2026 Adjusted EBITDA Amid Turnaround Efforts
During the Q3 2026 earnings call, Accendra Health (NYSE: ACH) management provided a cautious outlook regarding future profitability. New CEO Kenneth Gardner-Smith signaled that while there is long-term optimism for the company's trajectory, immediate turnaround actions are being implemented to address current challenges. The company warned investors that its 2026 adjusted EBITDA could fall as much as 30% below the previously anticipated $310 million midpoint. This downward revision reflects the complexities of the ongoing restructuring and the impact of strategic shifts intended to stabilize the business.
Topics: CEO appointment earnings call quarterly results
Read the full article at Seeking Alpha
Part of the story Accendra Health expects 2026 adjusted EBITDA could be up to 30% lower than $310M midpoint as turnaround actions begin (2 articles)